Skip to main content

HER2 therapy

Mark Pegram

  1. HER-2/neu status of the primary breast cancer (PBC) is determined by immunohistochemistry and fluorescent in situ hybridization. Because of a variety of technical factors, however, the PBC may not accurately refl...

    Authors: Walter P Carney, Kim Leitzel, Suhail Ali, Rainer Neumann and Allan Lipton
    Citation: Breast Cancer Research 2007 9:207
  2. Overexpression of the human epidermal growth factor receptor (HER)-2 oncogenic receptor tyrosine kinase, which occurs in 25% of breast cancers, portends poor clinical outcome and consequently represents an att...

    Authors: Neil Spector, Wenle Xia, Iman El-Hariry, Yossi Yarden and Sarah Bacus
    Citation: Breast Cancer Research 2007 9:205
  3. Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. The majority of patients with metastatic breast cancer who initially respond to trastuzumab develop resistance within on...

    Authors: Rita Nahta and Francisco J Esteva
    Citation: Breast Cancer Research 2006 8:215